{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T11:45:18Z","timestamp":1777203918949,"version":"3.51.4"},"posted":{"date-parts":[[2026,4,22]]},"group-title":"Cancer Biology","reference-count":48,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01GM109045"],"award-info":[{"award-number":["R01GM109045"]}]},{"name":"NIH","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>High-Grade Serous Ovarian Cancer (HGSOC) is the most lethal gynecological malignancy due to aggressive growth, widespread metastases, and high intra-tumoral heterogeneity. Poor prognosis is largely due to late diagnosis, hence there is an urgent need to identify novel biomarkers for screening, diagnosis, and monitoring. Here, we propose the voltage-dependent calcium channel hCaV1.2 encoded by CACNA1C as a potential biomarker and therapeutic target in HGSOC. Using IHC analysis for ten ovarian cancer patients, cytotoxicity assay, TCGA gene expression and survival analyses, homology modeling, molecular docking, Calcium channel membrane assembly and molecular dynamics simulations, we tested CACNA1C\u2019s role in HGSOC progression and the effect of blocking on cancer cell survival.<\/jats:p>\n                <jats:p>We show that nifedipine (NIFE), a calcium channel blocker (CCB), had a tumor suppressive effect based on binding models predicted by three-dimensional computer assisted molecular modeling and in vitro validation using human HGSOC cell line. Using The Cancer Genome Atlas ovarian public cohort, we found CACNA1C mRNA expression strongly correlated with poor patient survival for late-stage and metastasis than primary. We also show strong correlation of CACNA1C protein expression using immunohistochemistry correlating with COH ovarian carcinomas patients\u2019 disease progression. This research demonstrates that targeting HGSOC via CCBs may be therapeutically beneficial. By establishing further in vitro, in vivo, and clinical trials using FDA approved NIFE may be repurposed to target CACNA1C for HGSOC.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Novelty and Impact<\/jats:title>\n                  <jats:p>High-grade serous ovarian cancer (HGSOC) remains lethal due to late diagnosis and drug resistance. This study identifies CACNA1C (Cav1.2) as a novel prognostic biomarker and therapeutic target in HGSOC, showing that elevated expression correlates with metastatic\/recurrent disease and poor survival. Using molecular dynamics and in vitro models, we demonstrate that the FDA-approved calcium channel blocker nifedipine binds stably to Cav1.2 and suppresses tumor cell growth more effectively than cisplatin. These findings support repurposing nifedipine for biomarker-driven HGSOC therapy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Translational Relevance<\/jats:title>\n                  <jats:p>Late diagnosis and progressive relapses significantly contribute to the poor prognosis of ovarian cancer. Identification of a tumor biomarker that can be used for screening, diagnosis, and monitoring is critical for improving clinical outcome. Our findings demonstrate that CACNA1C is a viable diagnostic marker for HGSOC and that its blockade with CCBs reduces tumor progression, highlighting their therapeutic potential.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.04.19.719516","type":"posted-content","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:35:10Z","timestamp":1776900910000},"source":"Crossref","is-referenced-by-count":0,"title":["CACNA1C as a Prognostic Biomarker and Therapeutic Target in High-Grade Serous Ovari-an Cancer: Clinical Validation and Molecular Dynamics of Nifedipine Blockade"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9684-2506","authenticated-orcid":false,"given":"Mohamed A.","family":"Hammad","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, UH Seidman Cancer Center, University Hospitals and Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley Y.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of California, Riverside, Riverside, California, 92521 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eslam E.","family":"Abd El-Fattah","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, California, 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S.","family":"Aboody","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Beckman Research Institute, Duarte, California, 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-en A","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of California, Riverside, Riverside, California, 92521 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"1","key":"2026042604250738000_2026.04.19.719516v1.1","doi-asserted-by":"crossref","first-page":"28573","DOI":"10.1038\/s41598-024-80030-z","article-title":"Decoding the pathological and genomic profile of epithelial ovarian cancer","volume":"14","year":"2024","journal-title":"Scientific Reports"},{"key":"2026042604250738000_2026.04.19.719516v1.2","doi-asserted-by":"crossref","unstructured":"Huang J , Chan WC , Ngai CH , Lok V , Zhang L , Lucero-Prisno DE , 3rd, et al. Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers (Basel). 2022;14(9).","DOI":"10.3390\/cancers14092230"},{"key":"2026042604250738000_2026.04.19.719516v1.3","doi-asserted-by":"crossref","unstructured":"Dion L , Mimoun C , Nyangoh Timoh K , Bendifallah S , Bricou A , Collinet P , et al. Ovarian Cancer in the Elderly: Time to Move towards a More Logical Approach to Improve Prognosis-A Study from the FRANCOGYN Group. J Clin Med. 2020;9(5).","DOI":"10.3390\/jcm9051339"},{"issue":"38","key":"2026042604250738000_2026.04.19.719516v1.4","first-page":"635","article-title":"Ovarian cancer: diagnosis and treatment","volume":"108","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"2026042604250738000_2026.04.19.719516v1.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01022.x"},{"key":"2026042604250738000_2026.04.19.719516v1.6","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26300"},{"key":"2026042604250738000_2026.04.19.719516v1.7","doi-asserted-by":"crossref","unstructured":"Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23 Suppl 10:111-7.","DOI":"10.1093\/annonc\/mds300"},{"issue":"1","key":"2026042604250738000_2026.04.19.719516v1.8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13048-023-01292-1","article-title":"Cross talk of tumor protein D52 (TPD52) with KLF9, PKCepsilon, and MicroRNA 223 in ovarian cancer","volume":"16","year":"2023","journal-title":"J Ovarian Res"},{"key":"2026042604250738000_2026.04.19.719516v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2"},{"key":"2026042604250738000_2026.04.19.719516v1.10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00968"},{"key":"2026042604250738000_2026.04.19.719516v1.11","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6457"},{"key":"2026042604250738000_2026.04.19.719516v1.12","doi-asserted-by":"crossref","first-page":"135600","DOI":"10.1016\/j.neulet.2020.135600","article-title":"Genetic analyses of the endocannabinoid pathway in association with affective phenotypic variants","volume":"744","year":"2021","journal-title":"Neurosci Lett"},{"key":"2026042604250738000_2026.04.19.719516v1.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125766"},{"key":"2026042604250738000_2026.04.19.719516v1.14","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00909"},{"key":"2026042604250738000_2026.04.19.719516v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature12504"},{"issue":"3","key":"2026042604250738000_2026.04.19.719516v1.16","first-page":"938","article-title":"Retinoids as anti-cancer agents and their mechanisms of action","volume":"12","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2026042604250738000_2026.04.19.719516v1.17","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318236a2ec"},{"key":"2026042604250738000_2026.04.19.719516v1.18","doi-asserted-by":"crossref","first-page":"102444","DOI":"10.1016\/j.canep.2023.102444","article-title":"Association between antihypertensive medicine use and risk of ovarian cancer in women aged 50 years and older","volume":"86","year":"2023","journal-title":"Cancer Epidemiology"},{"key":"2026042604250738000_2026.04.19.719516v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04892-3"},{"key":"2026042604250738000_2026.04.19.719516v1.20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky427"},{"key":"2026042604250738000_2026.04.19.719516v1.21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw1132"},{"key":"2026042604250738000_2026.04.19.719516v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.04.043"},{"key":"2026042604250738000_2026.04.19.719516v1.23","unstructured":"Case DA , Aktulga HM , Belfon K , Ben-Shalom I , Brozell SR , Cerutti DS , et al. Amber 2021: University of California, San Francisco; 2021."},{"key":"2026042604250738000_2026.04.19.719516v1.24","unstructured":"Inc CCG. Molecular operating environment (MOE). Chemical Computing Group Inc. 1010 Sherbooke St. West, Suite# 910, Montreal \u2026; 2016."},{"key":"2026042604250738000_2026.04.19.719516v1.25","doi-asserted-by":"crossref","unstructured":"Edelsbrunner H , editor The union of balls and its dual shape. Proceedings of the ninth annual symposium on Computational geometry; 1993.","DOI":"10.1145\/160985.161139"},{"key":"2026042604250738000_2026.04.19.719516v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2005.12.005"},{"key":"2026042604250738000_2026.04.19.719516v1.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000880"},{"key":"2026042604250738000_2026.04.19.719516v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2009.04.013"},{"key":"2026042604250738000_2026.04.19.719516v1.29","doi-asserted-by":"publisher","DOI":"10.1063\/5.0012280"},{"key":"2026042604250738000_2026.04.19.719516v1.30","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20945"},{"key":"2026042604250738000_2026.04.19.719516v1.31","doi-asserted-by":"crossref","unstructured":"Wu EL , Cheng X , Jo S , Rui H , Song KC , D\u00e1vila-Contreras EM , et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. Wiley Online Library; 2014.","DOI":"10.1002\/jcc.23702"},{"key":"2026042604250738000_2026.04.19.719516v1.32","doi-asserted-by":"crossref","unstructured":"Kim S , Lee J , Jo S , Brooks III CL , Lee HS , Im W. CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules. Wiley Online Library; 2017.","DOI":"10.1016\/j.bpj.2016.11.1564"},{"key":"2026042604250738000_2026.04.19.719516v1.33","doi-asserted-by":"publisher","DOI":"10.1063\/1.470117"},{"key":"2026042604250738000_2026.04.19.719516v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9991(77)90098-5"},{"issue":"4","key":"2026042604250738000_2026.04.19.719516v1.35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1021\/acschemneuro.0c00684","article-title":"Inhibitory Mechanism of the Isoflavone Derivative Genistein in the Human CaV3","volume":"12","year":"2021","journal-title":"3 Channel. ACS Chemical Neuroscience"},{"issue":"6","key":"2026042604250738000_2026.04.19.719516v1.36","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/anie.202011793","article-title":"Structural Basis of the Modulation of the Voltage-Gated Calcium Ion Channel Cav1","volume":"60","year":"2021","journal-title":"1 by Dihydropyridine Compounds. Angewandte Chemie International Edition"},{"key":"2026042604250738000_2026.04.19.719516v1.37","doi-asserted-by":"crossref","first-page":"107776","DOI":"10.1016\/j.jmgm.2020.107776","article-title":"Effects of selective calcium channel blockers on ions\u2019 permeation through the human Cav1. 2 ion channel: A computational study","volume":"102","year":"2021","journal-title":"Journal of Molecular Graphics and Modelling"},{"issue":"2","key":"2026042604250738000_2026.04.19.719516v1.38","first-page":"379","article-title":"Binding mechanisms of 1, 4-dihydropyridine derivatives to L-type calcium channel Ca v 1.2: a molecular modeling study","volume":"12","year":"2016","journal-title":"Molecular BioSystems"},{"key":"2026042604250738000_2026.04.19.719516v1.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-010-9376-y"},{"key":"2026042604250738000_2026.04.19.719516v1.40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M007165200"},{"key":"2026042604250738000_2026.04.19.719516v1.41","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.2.235"},{"key":"2026042604250738000_2026.04.19.719516v1.42","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.55.3.336"},{"key":"2026042604250738000_2026.04.19.719516v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0263-7855(97)00009-X"},{"key":"2026042604250738000_2026.04.19.719516v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"2026042604250738000_2026.04.19.719516v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2171"},{"key":"2026042604250738000_2026.04.19.719516v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3105"},{"key":"2026042604250738000_2026.04.19.719516v1.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00699-2"},{"issue":"1","key":"2026042604250738000_2026.04.19.719516v1.48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-021-00830-z","article-title":"CACNA1C is a prognostic predictor for patients with ovarian cancer","volume":"14","year":"2021","journal-title":"Journal of ovarian research"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.04.19.719516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T11:25:22Z","timestamp":1777202722000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.04.19.719516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":48,"URL":"https:\/\/doi.org\/10.64898\/2026.04.19.719516","relation":{},"subject":[],"published":{"date-parts":[[2026,4,22]]},"subtype":"preprint"}}